Aura Biosciences, Inc. (AURA) stock
AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.11+0.00 (0.00%)
Close on Nov 13, 2026Market cap $737.34MP/E –Yield –
Aura Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Aura Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $105.35M, up 16.1% year over year. For fiscal 2025 it was $90.30M, up 23.2% from the year before. The highest annual figure on record is $90.30M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.30M | +23.2% |
| FY2024 | Dec 31, 2024 | $73.30M | +12.4% |
| FY2023 | Dec 31, 2023 | $65.23M | +54.4% |
| FY2022 | Dec 31, 2022 | $42.24M | +67.9% |
| FY2021 | Dec 31, 2021 | $25.16M | +39.5% |
| FY2020 | Dec 31, 2020 | $18.04M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.74M | +11.6% |
| Q2 FY2026 | Jun 30, 2026 | $30.75M | +34.4% |
| Q1 FY2026 | Mar 31, 2026 | $27.96M | +19.8% |
| Q4 FY2025 | Dec 31, 2025 | $21.90M | -2.0% |
| Q3 FY2025 | Sep 30, 2025 | $22.18M | +30.2% |
| Q2 FY2025 | Jun 30, 2025 | $22.88M | +35.6% |
| Q1 FY2025 | Mar 31, 2025 | $23.34M | +36.9% |
| Q4 FY2024 | Dec 31, 2024 | $22.33M | +10.1% |
| Q3 FY2024 | Sep 30, 2024 | $17.04M | +10.4% |
| Q2 FY2024 | Jun 30, 2024 | $16.88M | +11.6% |
| Q1 FY2024 | Mar 31, 2024 | $17.05M | +18.4% |
| Q4 FY2023 | Dec 31, 2023 | $20.28M | +54.1% |
| Q3 FY2023 | Sep 30, 2023 | $15.43M | +36.6% |
| Q2 FY2023 | Jun 30, 2023 | $15.12M | +59.0% |
| Q1 FY2023 | Mar 31, 2023 | $14.41M | +74.1% |
| Q4 FY2022 | Dec 31, 2022 | $13.16M | +64.9% |
| Q3 FY2022 | Sep 30, 2022 | $11.29M | +77.4% |
| Q2 FY2022 | Jun 30, 2022 | $9.51M | +43.4% |
| Q1 FY2022 | Mar 31, 2022 | $8.28M | +97.8% |
| Q4 FY2021 | Dec 31, 2021 | $7.98M | +125.2% |
| Q3 FY2021 | Sep 30, 2021 | $6.37M | +123.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.63M | – |
| Q1 FY2021 | Mar 31, 2021 | $4.19M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.54M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.85M | – |
See a number that looks wrong?